Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on modern management of frailty

LIVE: Thursday 17th October 2024, 18:00-19:30 (CEST)

Frailty has a significant impact on health and wellbeing, especially in older adults. Join our experts to understand the factors that contribute to the development of frailty and find out how to manage the condition and reduce the risk of disability, dependency, and mortality.
ADVANCED SEARCH
Log in
Top
Current Hypertension Reports

31-05-2024 | Hypertension | Inflammation and Cardiovascular Diseases (A Kirabo, Section Editor)

Hypertension and Cardiovascular Outcomes in Inflammatory and Autoimmune Diseases: A Systematic Review and Meta-analysis

Authors: Marie Barozet, Olivier Le Tilly, Theodora Bejan-Angoulvant, Pierre Fesler, Camille Roubille

Published in: Current Hypertension Reports

Login to get access

Abstract

Purpose

This review aimed to investigate the prevalence of hypertension and cardiovascular (CV) complications in various inflammatory and autoimmune diseases (IAD).

Recent Findings

Despite recent improvements in the management of IAD, patients with IAD still have an increased CV mortality and CV complications, mostly related to CV risk factors such as hypertension and inflammation.

Summary

We systematically searched MEDLINE and EMBASE libraries for controlled studies involving hypertension and CV complications in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), psoriasis including psoriatic arthritis (PsA), Sjogren’s syndrome (SS), or antineutrophil cytoplasmic antibody-associated vasculitis (AAV) between January 2000 and March 2022. We extracted data on the prevalence of hypertension and CV complications. Then, random-effects meta-analyses and exploratory multivariate meta-regression were performed to explore factors related to the prevalence of hypertension. Of 2726 studies screened, 122 were selected for the meta-analysis. The prevalence of hypertension was higher among patients with IAD than controls, with an overall unadjusted odds ratio (OR) [95% confidence interval] of 1.67 [1.58–1.76] and an adjusted OR of 1.36 [1.24–1.50]. All diseases were found to be associated with increased risk of hypertension: SLE, adjusted OR 3.40 [1.93–6.00]; psoriasis, OR 1.32 [1.16–1.51]; PsA, OR 1.49 [1.15–1.94]; RA, OR 1.28 [1.04–1.58]; SS, OR 2.02 [1.19–3.44]. Age and female sex were significantly associated with hypertension in patients with IAD. The risk of CV complications was increased: ischemic heart disease, adjusted OR 1.38 [1.21–1.57]; cerebrovascular disease, OR 1.37 [1.03–1.81]; heart failure, OR 1.28 [1.05–1.55]; atherosclerotic plaques presence, OR 2.46 [1.84–3.29]. The prevalence of hypertension and CV complications is higher among patients with IAD. Screening and management of hypertension appears to be of paramount importance in these patients.
Appendix
Available only for authorised users
Literature
1.
2.
•• Conrad N, et al. Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK. Lancet Lond Engl. 2022;400:733–43. Findings from this study show that despite improvements in the management of AD, these diseases remain associated with increased CV mortality and CV complications.CrossRef
3.
Schoenfeld SR, Kasturi S, Costenbader KH. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthritis Rheum. 2013;43:77–95.CrossRefPubMed
4.
Hak AE, Karlson EW, Feskanich D, Stampfer MJ, Costenbader KH. Systemic lupus erythematosus and the risk of cardiovascular disease: Results from the nurses’ health study. Arthritis Care Res. 2009;61:1396–402.CrossRef
5.
Lu X, et al. Patients with systemic lupus erythematosus face a high risk of cardiovascular disease: a systematic review and Meta-analysis. Int Immunopharmacol. 2021;94:107466.CrossRefPubMed
6.
Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis. 2012;71:1524–9.CrossRefPubMed
7.
8.
Ogdie A, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis. 2015;74:326–32.CrossRefPubMed
9.
• Sun G, et al. Long-term risk of heart failure and other adverse cardiovascular outcomes in primary Sjögren’s syndrome. J Intern Med. 2022. https://​doi.​org/​10.​1111/​joim.​13595. This study compared Danish patients with primary Sjogren's syndrom diagnosed between 1996 and 2018 to the general population. It revealed a higher rate of incident heart failure and other cardiovascular outcomes in patients with Sjogren's syndrome.CrossRefPubMed
10.
Houben E, et al. Cardiovascular events in anti-neutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis of observational studies. Rheumatol Oxf Engl. 2018;57:555–62.CrossRef
11.
Mercuzot C, et al. Comorbidities and health-related quality of life in Patients with Antineutrophil Cytoplasmic Antibody (ANCA) - associated vasculitis. Autoimmun Rev. 2021;20:102708.CrossRefPubMed
12.
13.
Hallajzadeh J, et al. The association between metabolic syndrome and its components with systemic lupus erythematosus: a comprehensive systematic review and meta-analysis of observational studies. Lupus. 2018;27:899–912.CrossRefPubMed
14.
15.
Munguia-Realpozo P, et al. Systemic lupus erythematosus and hypertension. Autoimmun Rev. 2019;18:102371.CrossRefPubMed
16.
Giannelou M, Mavragani CP. Cardiovascular disease in systemic lupus erythematosus: a comprehensive update. J Autoimmun. 2017;82:1–12.CrossRefPubMed
17.
Ballocca F, et al. Predictors of cardiovascular events in patients with systemic lupus erythematosus (SLE): a systematic review and meta-analysis. Eur J Prev Cardiol. 2015;22:1435–41.CrossRefPubMed
18.
Bartoloni E, et al. The prevalence and relevance of traditional cardiovascular risk factors in primary Sjögren’s syndrome. Clin Exp Rheumatol. 2018;36(Suppl 112):113–20.PubMed
19.
Roubille C, et al. Impact of cardiovascular risk factors on the occurrence of cardiovascular events in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides. J Clin Med. 2021;10:2299.CrossRefPubMedPubMedCentral
20.
Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [abstract]. Symposium on Systematic Reviews: Beyond the Basics. 2000 Jul 3-5. UK: Oxford; 2000. p. 15.
21.
Duval S, Tweedie RA. Nonparametric trim and fill method of accounting for publication bias in meta-analysis. J Am Stat AssocJ AMER Stat ASSN. 2000;95:89–98.
22.
Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies. J Hypertens. 2013;31:433–42.CrossRefPubMed
23.
Juarez M, et al. Cardiovascular risk factors in women with primary Sjögren’s syndrome: United Kingdom primary Sjögren’s syndrome registry results. Arthritis Care Res. 2014;66:757–64.CrossRef
24.
25.
de Leeuw K, et al. Patients with Wegener’s granulomatosis: a long-term follow-up study. Clin Exp Rheumatol. 2010;28:18–23.PubMed
26.
Baghdadi LR, Woodman RJ, Shanahan EM, Mangoni AA. The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis. PLoS ONE. 2015;10:e0117952.CrossRefPubMedPubMedCentral
27.
Hu MY, Yang Q, Zheng J. The association of psoriasis and hypertension: focusing on anti-inflammatory therapies and immunological mechanisms. Clin Exp Dermatol. 2020;45:836–40.CrossRefPubMed
28.
Anyfanti P, Gavriilaki E, Douma S, Gkaliagkousi E. Endothelial dysfunction in patients with rheumatoid arthritis: the role of hypertension. Curr Hypertens Rep. 2020;22:56.CrossRefPubMed
29.
Lee M-S, Chang C-H, Lin R-Y, Lai M-S. Risks of hypertension associated with cyclosporine, nonsteroidal anti-inflammatory drugs, and systemic glucocorticoids in patients with psoriasis: a nationwide population-based nested case-control study in Taiwan. Pharmacoepidemiol Drug Saf. 2016;25:133–40.CrossRefPubMed
30.
Riley RD, et al. Meta-analysis of continuous outcomes combining individual patient data and aggregate data. Stat Med. 2008;27:1870–93.CrossRefPubMed
31.
32.
Roubille F, Kritikou EA, Roubille C, Tardif J-C. Emerging anti-inflammatory therapies for atherosclerosis. Curr Pharm Des. 2013;19:5840–9.CrossRefPubMed
33.
34.
Goodson NJ, et al. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum. 2005;52:2293–9.CrossRefPubMed
35.
Arkema EV, Svenungsson E, Von Euler M, Sjöwall C, Simard JF. Stroke in systemic lupus erythematosus: a Swedish population-based cohort study. Ann Rheum Dis. 2017;76:1544–9.CrossRefPubMed
36.
Ikdahl E, et al. Guideline recommended treatment to targets of cardiovascular risk is inadequate in patients with inflammatory joint diseases. Int J Cardiol. 2019;274:311–8.CrossRefPubMed
37.
38.
• Mancia Chairperson G, et al. ESH Guidelines for the management of arterial hypertension. the task force for the management of arterial hypertension of the european society of hypertension endorsed by the european renal association (ERA) and the international society of hypertension (ISH). J Hypertens. 2023. https://​doi.​org/​10.​1097/​HJH.​0000000000003480​. This paper report the current guidelines for the management of arterial hypertension, with a few specific recommendations for AD, such as reducing inflammation, limiting the use of NSAIDs and using calcium channel blockers and renin-angiotensin-aldosterone system inhibitors.CrossRef
39.
Visseren FLJ, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42:3227–337.CrossRefPubMed
40.
Peters MJL, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010;69:325–31.CrossRefPubMed
41.
Roubille C, et al. Evidence-based recommendations for the management of comorbidities in rheumatoid arthritis, psoriasis, and psoriatic arthritis: expert opinion of the canadian dermatology-rheumatology comorbidity initiative. J Rheumatol. 2015;42:1767–80.CrossRefPubMed
42.
Bramlage CP, et al. Management of cardiovascular risk factors in patients with ANCA-associated vasculitis. J Eval Clin Pract. 2017;23:747–54.CrossRefPubMed
43.
Smolen JS, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79:685–99.CrossRefPubMed
44.
Agca R, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2017;76:17–28.CrossRefPubMed
45.
• Drosos GC, et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis. 2022;81:768–79. This article provides recent recommendations for cardiovascular risk management in gout, vasculitis, systemic sclerosis, myositis, mixed connective tissue disease, Sjogren’s syndrome, systemic lupus erythematosus and antiphospholipid syndrome. Authors suggest a blood pressure target <130/80 mm Hg in systemic lupus erythematosus.CrossRefPubMed
46.
• Coates LC, et al. Group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18:465–79. This articles provides updated recommendations for the management of psoriasis and psoriatic arthritis. Authors underline that cardiovascular risk is more elevated in those patients, justifying careful screening and management of modifiable cardiovascular risk factors such as hypertension.CrossRefPubMedPubMedCentral
Metadata
Title
Hypertension and Cardiovascular Outcomes in Inflammatory and Autoimmune Diseases: A Systematic Review and Meta-analysis
Authors
Marie Barozet
Olivier Le Tilly
Theodora Bejan-Angoulvant
Pierre Fesler
Camille Roubille
Publication date
31-05-2024
Publisher
Springer US
Published in
Current Hypertension Reports
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-024-01311-6

EASD 2024

‘Noninferior’ reduction of type 1 diabetes HbA1c by weekly insulin efsitora alfa

Weekly treatment with insulin efsitora is noninferior to daily insulin degludec for the reduction of HbA1c in adults with type 1 diabetes, show the findings of the QWINT-5 trial.

Read more

Weight loss with new obesity drug amycretin

Tirzepatide significantly reduces UACR in individuals with obesity and type 2 diabetes

Liraglutide reduces BMI for young children with obesity

» View more highlights on the EASD 2024 hub page

2024 ESC Congress

Noise pollution dangerous for heart health

Two studies underscore the adverse impact of noise pollution on the risk for and prognosis after myocardial infarction.

Read more

Post-TAVI follow up: deploying virtual assistants

Antihypertensives: more effective at morning or night?

Low Lp(a) levels unlikely to increase the risk of diabetes

» View more highlights on the 2024 ESC Congress hub page

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more
Image Credits